HBHannah M. Baumann

Hannah M. Baumann

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Hannah M. Baumann has a total of 94 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Large-Scale Collaborative Assessment of Binding Free Energy Calculations for Drug Discovery Using OpenFE

    by Hannah M. Baumann, Joshua T. Horton, Michael M. Henry, Alyssa Travitz, Benjamin Ries, Richard J. Gowers, David W. H. Swenson, Iván Pulido, Dominic Rufa, David L. Dotson, et al.

    Accurately measuring compound binding affinities is key to driving the pharmaceutical development process. Rigorous physics-based in silico approaches, particularly alchemical free energy methods, have become a gold-standard tool for estimating compound affinity changes. Here we present the results of a large-scale precompetitive collaborative assessment of relative binding free energy (RBFE) calculations generated by 15 pharmaceutical companies. We evaluate an open-source and MIT-licensed RBFE protocol from the Open Free Energy (OpenFE) ecosystem across both public and blinded private datasets, encompassing over 1,700 ligands in total. For the public dataset, the weighted RMSE across the 58 systems was 1.731.531.96 kcal/mol, with 10 of the systems reaching sub-kcal/mol accuracy. For the private dataset, the weighted RMSE across the 37 systems was 2.441.943.06 kcal/mol, with only 2 of the systems reaching sub-kcal/mol accuracy, reflecting the increased complexity of real-world drug discovery. The protocol's performance was system-dependent, with no single dominant error source, indicating that accuracy is primarily influenced by input quality and transformation type. Overall, these benchmark results are encouraging and indicate that OpenFE is ready for large-scale industrial applications, with an "out-of-the-box" accuracy that approaches that of commercial solutions. While comparison against published FEP+ results, which were obtained after manual parameter optimization, shows comparable ranking statistics, a gap remains in error statistics, for which we outline possible paths toward improvement. The protocol meets key criteria required for production use in an industrial setting: it shows robust performance, generates reproducible results, and achieves both sufficient throughput and rapid convergence.


  • Open Access

    Large-scale collaborative assessment of binding free energy calculations for drug discovery using OpenFE

    by Hannah M. Baumann, Joshua T. Horton, Michael M. Henry, Alyssa Travitz, Benjamin Ries, Richard J. Gowers, David W. H. Swenson, Iván Pulido, Dominic Rufa, David L. Dotson, et al.

    Accurately measuring compound binding affinities is key to driving the pharmaceutical development process. Rigorous physics-based in silico approaches, particularly alchemical free energy methods, have become a gold standard tool for estimating compound affinity changes. Here we present the results of a large-scale pre-competitive collaborative assessment of relative binding free energy (RBFE) calculations generated by 15 pharmaceutical companies. We evaluate an open-source and MIT licensed RBFE Protocol from the Open Free Energy (OpenFE) ecosystem across both public and blinded private datasets, encompassing over 1,700 ligands in total. For the public dataset, the weighted RMSE across the 58 systems was 1.73 [1.53, 1.96] kcal/mol, with 10 of the systems reaching sub-kcal/mol accuracy. For the private dataset, the weighted RMSE across the 37 systems was 2.44 [1.94, 3.06] kcal/mol, with only 2 of the systems reaching sub-kcal/mol accuracy, reflecting the increased complexity of real-world drug discovery. The protocols performance was system-dependent, with no single dominant error source, indicating that accuracy is primarily influenced by input quality and transformation type. Overall, these benchmark results are encouraging and indicate that OpenFE is ready for large-scale industrial applications, with an "out-of-the-box" accuracy that approaches that of commercial solutions. While comparison against published FEP+ results, which were obtained after manual parameter optimization, shows comparable ranking statistics, a gap remains in error statistics, for which we outline possible paths toward improvement. The protocol meets key criteria required for production use in an industrial setting: it shows robust performance, generates reproducible results, and achieves both sufficient throughput and rapid convergence.


  • Open Access

    Efficient Binding Affinity Estimation for Fragment-Based Compounds Using a Separated Topologies Approach

    by Ana-Maria Caldaruse, Hannah M. Baumann, David L. Mobley

    Fragment-based drug discovery (FBDD) is a widely used strategy in early-stage drug development, but accurately predicting the binding affinities of fragments and their elaborated analogs poses unique computational challenges. These difficulties arise from weak binding affinities, diverse chemical scaffolds, and limited structural overlap between fragments and their optimized derivatives. While several free-energy methods exist, few are tailored to the specific requirements of FBDD. In this study, we evaluate the Separated Topologies (SepTop) approach for modeling fragment-based transformations, including fragment merging and linking. Using retrospective data sets from Cyclophilin D and SARS-CoV-2 Macrodomain 1, we demonstrate that SepTop can recover experimental binding affinities with good accuracy across both fragment and lead-like compounds. These results support SepTop's suitability for fragment optimization and highlight its potential to extend the reach of binding free-energy calculations into earlier stages of drug discovery.


  • Open Access

    Large-scale collaborative assessment of binding free energy calculations for drug discovery using OpenFE

    by Hannah M. Baumann, Joshua T. Horton, Michael M. Henry, Alyssa Travitz, Benjamin Ries, Richard J. Gowers, David W. H. Swenson, Iván Pulido, Dominic Rufa, David L. Dotson, et al.

    Accurately measuring compound binding affinities is key to driving the pharmaceutical development process. Rigorous physics-based in silico approaches, particularly alchemical free energy methods, have become a gold standard tool for estimating compound affinity changes. Here we present the results of a large-scale pre-competitive collaborative assessment of relative binding free energy (RBFE) calculations generated by 15 pharmaceutical companies. We evaluate an open-source and MIT licensed RBFE Protocol from the Open Free Energy (OpenFE) ecosystem across both public and blinded private datasets, encompassing over 1,700 ligands in total. For the public dataset, the weighted RMSE across the 58 systems was 1.73 [1.53, 1.96] kcal/mol, with 10 of the systems reaching sub-kcal/mol accuracy. For the private dataset, the weighted RMSE across the 37 systems was 2.44 [1.94, 3.06] kcal/mol, with only 2 of the systems reaching sub-kcal/mol accuracy, reflecting the increased complexity of real-world drug discovery. The protocols performance was system-dependent, with no single dominant error source, indicating that accuracy is primarily influenced by input quality and transformation type. Overall, these benchmark results are encouraging and indicate that OpenFE is ready for large-scale industrial applications, with an "out-of-the-box" accuracy that approaches that of commercial solutions. While comparison against published FEP+ results, which were obtained after manual parameter optimization, shows comparable ranking statistics, a gap remains in error statistics, for which we outline possible paths toward improvement. The protocol meets key criteria required for production use in an industrial setting: it shows robust performance, generates reproducible results, and achieves both sufficient throughput and rapid convergence.


  • Open Access

    Evaluating the functional importance of conformer-dependent atomic partial charge assignment

    by Meghan Osato, Hannah Baumann, Jennifer Huang, Irfan Alibay, David Mobley

    Physics-based methods such as protein-ligand binding free energy calculations have been increasingly adopted in early-stage drug discovery to prioritize promising compounds for synthesis. However, the accuracy of these methods is highly dependent on details of the calculation and choices made while preparing the ligands and protein ahead of running calculations. During ligand preparation, researchers typically assign partial atomic charges to each ligand atom using a specific ligand conformation for charge assignment, often the input conformer. While it is a well known problem that partial charge assignment is dependent on conformation, little investigation has explored the downstream effects of varied partial charge assignment on free energy estimates. Preliminary benchmarks from Open Free Energy Project show that generating partial charges from different input conformers leads to variation of up to ±5.3 kcal/mol in calculated relative binding free energies due to variation in partial charges alone. In this study, we more systematically explore this issue, investigating systems where differences in partial charge generation (such as those caused by input conformer choice, partial charge engine, and hardware) may lead to differences in calculated absolute hydration free energy (AHFE) values. We demonstrate that supplying different input conformers to a partial charge engine can result in atomic partial charge discrepancies of up to 0.681 e, resulting in differences in calculated AHFE of 6.9 ± 0.1 kcal/mol. We find that even relatively small variations in partial charge assignment can result in notable differences in calculated AHFE, and thus care should be taken when assigning partial charges to ensure reproducibility and accuracy of any resulting free energy calculations.


  • Konnektor: A Framework for Using Graph Theory to Plan Networks for Free Energy Calculations

    by Benjamin Ries, Richard J. Gowers, Hannah M. Baumann, David W. H. Swenson, Michael M. Henry, James R. B. Eastwood, Irfan Alibay, David Mobley

    Alchemical free energy campaigns can be planned using graph theory by building networks that contain nodes representing molecules that are connected by possible transformations as edges. We introduce Konnektor, an open-source Python package, for systematically planning, modifying, and analyzing free energy calculation networks. Konnektor is designed to aid in the drug discovery process by enabling users to easily setup free energy campaigns using complex graph manipulation methods. The package contains functions for network operations including concatenation of networks, deletion of transformations, and clustering of molecules along with a framework for combining these tools with existing network generation algorithms to enable the development of more complex methods for network generation. A comparison of the various network layout features offered is carried out using toy data sets. Additionally, Konnektor contains visualization and analysis tools, making the investigation of network features much simpler. Besides the content of the package, the paper also offers application examples, demonstrating how Konnektor can be used and how the different networks perform from a graph theory perspective. Konnektor is freely available via GitHub at https://github.com/OpenFreeEnergy/konnektor under the permissive MIT License.


  • Open Access

    Broadening the scope of binding free energy calculations using a Separated Topologies approach

    by Hannah M. Baumann, Eric Dybeck, Christopher Lee McClendon, Frank C. Pickard Iv, Vytautas Gapsys, Laura Pérez-Benito, David F. Hahn, Gary Tresadern, Alan M. Mathiowetz, David L. Mobley

    Binding free energy calculations predict the potency of compounds to protein binding sites in a physically rigorous manner and see broad application in prioritizing the synthesis of novel drug candidates. Relative binding free energy calculations (RBFE) have emerged as an industry standard approach to achieve highly accurate rank-order predictions of the potency of related compounds; however, this approach requires that the ligands share a common scaffold and a common binding mode, restricting the methods' domain of applicability. This is a critical limitation, since complex modifications to the ligands, especially core hopping, are very common in drug design. Absolute Binding Free Energy calculations (ABFE) are an alternate method, which can be used for ligands that are not congeneric. However, ABFE suffer from a known problem of long convergence times, due to the need to sample additional degrees of freedom within each system, such as sampling rearrangements necessary to open and close the binding site. Here, we report on an alternative method for RBFE, called Separated Topologies (SepTop), which overcomes the issues in both of the aforementioned methods, by enabling large scaffold changes between ligands with a convergence time comparable to traditional RBFE. Instead of only mutating atoms that vary between two ligands, this approach performs two absolute free energy calculations at the same time in opposite directions, one for each ligand. Defining the two ligands independently allows the comparison of binding of diverse ligands without the artificial constraints of identical poses or a suitable atom-atom mapping. This approach also avoids the need to sample the unbound state of the protein, making it more efficient than absolute binding free energy calculations. Here, we introduce an implementation of SepTop. We developed a general and efficient protocol for running SepTop, and we demonstrated the method on four diverse, pharmaceutically relevant systems. Here we report the performance of the method, as well as our practical insights into strengths, weaknesses, and challenges of applying this method in an industrial drug design setting. We find that the accuracy of the approach is sufficiently high to rank order ligands with an accuracy comparable to traditional RBFE calculations, while maintaining the additional flexibility of SepTop.